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Abstract
Previously, TRAIL has been shown to activate mitogen-activated protein kinases (MAPKs)
depending on caspase and Mst1 activations. However, the upstream molecule of the MAPKs has
not yet been clearly elucidated. MEKK1 and ASK1 as possible candidates for the action of
MAPKKKs induced by TRAIL and the possibility of ROS involvement were investigated.
MEKK1/MEKK4 rather than ASK1 are responsible for TRAL-induced JNK or p38 activation, and
their catalytic activity were repressed by caspase 8 inhibitor suggesting caspase 8 activation
induced by TRAIL was indispensible for MEKK activation. 14-3-3 θ was also shown to interact
with and to dissociate from MEKK1 by TRAIL treatment, which implicates the possibility of
14-3-3 protein as a negative regulator of MEKK1 activation. Taken together, here we show that
the upstream molecule of TRAIL-induced MAPKs activation is MEK kinase (MEKK), rather than
ASK1, through mediation of its signal to JNK/p38 in a caspase 8-dependent manner.
Keywords
MEKK1/4; TRAIL; JNK; p38; 14-3-3
Introduction
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), also known as
Apo2 ligand, is a type II transmembrane protein belonging to the TNF superfamily (1,2).
The binding of TRAIL to its receptors (DR4/TRAIL-R1 and DR5/TRAIL-R2) results in
receptor aggregation and recruitment of the FADD (Fas-associated death domain) adaptor
proteins, which subsequently induce the formation of the death-inducing signaling complex
(DISC) involved in the activation of the caspase 8 initiator (3,4). Activated caspase 8
cleaves Bid and/or caspase 3 and initiates the mitochondrial apoptotic pathway (intrinsic
¶All correspondence should be addressed to Dr. Jae J. Song, Institute for Cancer Research, Yonsei Cancer Center, Yonsei University,
250 Seongsanno, Seodaemun-gu, Seoul, Korea; Tel: 82-2-2228-8037, Fax: 82-2-392-1508, jjs109@yuhs.ac.
*Equally contributed
NIH Public Access
Author Manuscript
Oncol Rep. Author manuscript; available in PMC 2011 March 1.
Published in final edited form as:
Oncol Rep. 2011 February ; 25(2): 537–544. doi:10.3892/or.2010.1079.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
pathway) and/or the caspase cascade (extrinsic pathway), respectively, eventually leading to
cell death (5).
Many reports indicate that TRAIL kills a variety of tumor cell lines, while leaving normal
cells viable, which suggests that this protein may function as a specific cancer therapeutic
agent (6). Although TRAIL is regarded as a potential anticancer agent, a considerable
proportion of cancer cells, especially some highly malignant tumors, are resistant to
apoptosis induction by TRAIL, and some cancer cells that are initially sensitive to TRAIL-
induced apoptosis can become resistant after repeated exposure (acquired resistance) (7).
However, the exact mechanisms of acquired TRAIL resistance are still largely unknown.
Recently, we reported that Src, c-Cbl, and PI3K are involved in the phosphorylation of Akt
during TRAIL treatment, and these phosphorylations are related to TRAIL-induced acquired
resistance (8,9). In addition to the non-apoptotic TRAIL signaling of Akt phosphorylation,
TRAIL also induces the activation of MAPK kinase pathways in a caspase 8-dependent
manner (10–12). However, the biological roles of JNK and p38 MAPK activations in
TRAIL-induced signaling are uncertain (5). Moreover, multiple mechanisms by which JNK
or p38 are activated by TRAIL have been reported. For example, Varfolmeev et al. (11)
suggested that FADD, caspase-8, RIP1, and TRAF2 are recruited within the primary death-
inducing signaling complex (DISC), leading to the stimulations of JNK and p38, while Liu
et al. (13) concluded that MEKK1 could be activated via TRAF2 and RIP to activate JNK in
the absence of apoptotic conditions. We demonstrated the occurrence of Mst1-mediated
caspase 8-dependent activation of mitogen-activated protein kinases (MAPKs) during
TRAIL incubation, but the upstream entities of the MAPKs remain unidentified.
The MAPKs are a family of kinases that transduce external signals to the nucleus in order to
decide the fate of the cell (14). Usually, conventional MAPKs consist of three family
members, JNK, p38, and ERK, which are involved in different cellular processes, including
inflammation, cell proliferation and differentiation, and apoptosis (5). Notwithstanding the
TRAIL-induced ERK activation, which is mainly associated with an anti-apoptotic function,
the functions of JNK and p38 activation in TRAIL-induced signaling are varied and can be
controversial depending on the cell types and cellular contexts involved (15–20). However,
the upstream molecules of the MAPKs have not yet been classified. Actually, MAPKKKs
link a variety of extracellular stimuli to cytoplasmic and nuclear effectors by activating
downstream MAPK pathways (21). MEKK1, ASK1, TAK1, and MLK2 are well-known
MAP3 kinases (22). In this study, we clearly demonstrate that MEKK1 and MEKK4
transmit TRAIL-induced signals to JNK or p38 MAPK in caspase 8-dependent manners.
Materials and Methods
Cell culture
A human prostate adenocarcinoma cell line, DU-145, was cultured in Dulbecco’s modified
Eagle’s medium (DMEM) with 10% fetal bovine serum (FBS) (HyClone, Logan, UT, USA)
and 26 mM sodium bicarbonate. The cells were maintained in a humidified environment
containing 5% CO2 and air at 37 °C.
Reagents and antibodies
Polyclonal anti-phospho-ERK, anti-ERK, anti-p38, monoclonal anti-phospho-p38, and anti-
caspase-8 were purchased from Cell Signaling (Beverly, MA, USA), and anti-ACTIVE
(phosphoT183 and phosphoY185) JNK was purchased from Promega (Madison, WI, USA).
Polyclonal anti-JNK1 and 14-3-3 β, γ, θ, and ζ were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-MEKK1 was purchased from Assay
Designs (Ann Arbor, MI, USA). Anti-ASK1 was purchased from Millipore (Billerica, MA,
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USA). Monoclonal anti-PARP was purchased from Biomol International, L.P. (Plymouth
Meeting, PA, USA). Anti-actin antibody was purchased from ICN (Costa Mesa, CA, USA).
Caspase-8 inhibitor (Z-IETD-FMK) was purchased from Calbiochem (San Diego, CA,
USA). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Protein extracts and polyacrylamide gel electrophoresis
Cells were lysed with 1× Laemmli lysis buffer (2% sodium dodecyl sulfate, 10% glycerol,
0.002% bromophenol blue, 62.5 mM Tris [pH 6.8]) and boiled for 10 min. Protein content
was measured using BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). The samples
were diluted with 1× lysis buffer, and β-mercaptoethanol was added until a concentration of
350 mM was achieved. Then, equal amounts of protein were loaded onto 10% sodium
dodecyl sulfate (SDS) polyacrylamide gels. SDS-polyacrylamide gel electrophoresis
(PAGE) analysis was performed according to the procedure of Laemmli using a Hoefer gel
apparatus.
Immunoblot analysis
Proteins were separated by SDS-PAGE and electrophoretically transferred to nitrocellulose
membranes. Each nitrocellulose membrane was blocked with 5% nonfat dry milk in PBS-
Tween-20 (0.1%, v/v) at 4°C overnight. The membrane was then incubated with the primary
antibody (diluted according to the manufacturer’s instructions) for 2 hr. Horseradish
peroxidase-conjugated anti-rabbit or anti-mouse IgG was used as the secondary antibody.
Immunoreactive proteins were visualized by chemiluminescence (ECL, Amersham,
Arlington Heights, IL, USA).
Immune complex kinase assay
For the immune complex kinase assay, DU-145 cells were lysed after TRAIL treatment in a
buffer solution containing 20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EGTA, 10 mM
NaF, 1% Triton X-100, 0.5% deoxycholate, 2 mM DTT, 1 mM sodium orthovanadate, 1
mM PMSF, and protein inhibitor cocktail solution (Sigma-Aldrich). Cell extracts were
clarified using centrifugation, and the supernatants were immunoprecipitated with mouse
anti-MEKK1 or anti-MEKK4 antibody and protein G agarose (Santa Cruz Biotechnology,
Inc.). The beads were washed twice with a solution containing 150 mM NaCl, 20 mM Tris-
HCl (pH 7.5), 5 mM EGTA, 2 mM DTT, 1 mM sodium orthovanadate, 1 mM PMSF, and
protein inhibitor cocktail solution, washed once more with the kinase buffer solution, and
then were subjected to kinase assays. To examine the catalytic activity of MEKK1 or
MEKK4, GST-tagged JNK1 and SEK1 proteins were used as substrates. For the purification
of JKN1 or SEK1, the plasmid containing GST-human JNK1 for bacterial fusion protein
was constructed in pGEX-4T-1 by inserting the HindIII/XbaI fragment, followed by Klenow
treatment with pcDNA3-JNK1. The expression of GST-JNK1 protein was confirmed by
Western blotting and purified using glutathione-Sepharose 4B (Amersham Biosciences).
GST-SEK1 was purified from ten plates of 293 cells transfected with the pEBG/SEK1
(kindly provided by J. M. Kyriakis, Massachusetts General Hospital, Charlestown, MA), and
the purification step was performed as described previously (23). To measure the immune
complex activity of MEKK1 or MEKK4, 0.2 μg GST-SEK1 was first incubated with the
immune complexes for 10 min at 30 °C in a final volume of 25 μl of a solution containing
20 mM Tris-HCl (pH 7.5), 20 mM MgCl2, and 100 μM ATP and then with 1 μg GST-JNK1
for 10 min at 30 °C. Thereafter, the activated complex was subjected to SDS-PAGE, and the
phosphorylated JNK1 was analyzed using rabbit anti-ACTIVE JNK antibody.
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RNA Interference by siRNA of SEK1
To stably express siRNA for the long-term knockdown, pSilencer 2.1-U6 hygro vector
(Ambion, Inc., Austin, TX) was used for clonal cell lines. The inserts for hairpin siRNA into
pSilencer were prepared by annealing two oligonucleotides. For human SEK1 siRNA, the
top strand sequence was 5_-
GATCCACGCAAAGCACTGAAGTTGTTCAAGAGACAACTTCAGTGCTTTGCGTTT
TTTTGGAAA-3, and the bottom strand sequence was 5-
AGCTTTTCCAAAAAAACGCAAAGCACTGAAGTTGTCTCTTGAACAACTTCAGTG
CTTTGCGTG-3. The annealed insert was cloned into pSilencer 2.1-U6 hygro digested with
BamHI and HindIII. The correct structure of pSilencer 2.1-U6 hygro-SEK1 was confirmed
by nucleotide sequencing. The resultant plasmid, pSilencer-SEK1, was transfected into
DU-145 cells, and hygromycin B (250 μg/ml)-resistant cell clones were isolated. The
interference of SEK1 protein expression was confirmed by immunoblot using anti-SEK1
(Cell Signaling) antibody. To down regulate ASK1, MEKK1 or MEKK4, their respective
siRNAs (Santa Cruz Biotechnology, Inc.) were used. Cells were transfected with each
siRNA and incubated for 36 hr. The interference of ASK1, MEKK1, or MEKK4 protein
expression was confirmed by immunoblotting using the anti-ASK1 antibody, anti-MEKK1
antibody, or anti-MEKK4 antibody, respectively.
Results
MEKK1 rather than ASK1 is the upstream molecule of TRAIL-induced JNK activation
We previously observed that TRAIL-induced MAPKs activation is dependent on caspase
activation, and that Mst1 (mammalian sterile 20-like kinase 1) mediates caspase activation
and MAPKs activation (12). However, the upstream molecule of MAPKs by TRAIL has not
yet been clarified. Here, we show that TRAIL-induced JNK activation is dependent on
MEKK1, rather than ASK1, and caspase 8 activations. First of all, we examined which
MAPKKK is involved in MAPKs activation during TRAIL treatment. For this purpose,
MEKK1 and ASK1 were chosen and down regulated using siRNA of MEKK1 or ASK1;
then, the phosphorylation of each of the MAPKs was examined. As shown in figures 1A and
1B, ASK1 and ROS production were not involved in TRAIL-induced MAPKs activation,
whereas MEKK1 was closely related to the TRAIL-induced JNK activation.
MEKK1 catalytic activation induced by TRAIL is caspase 8-dependent
Next, we investigated whether the MEKK1 catalytic activation is really increased by TRAIL
and whether the activation is related to caspase 8 activation, as suggested by many
controversial reports. For the estimation of MEKK1 catalytic activity, its downstream
substrates SEK1 (MKK4) and JNK1 were used for the consecutive substrates MEKK1 and
SEK1, respectively; then, immunoprecipitation of MEKK1 after TRAIL treatment was
performed using the MEKK1 antibody for an in vitro immunocomplex kinase assay. As
expected based upon our previous experience (12), increased MEKK1 activity by TRAIL
was repressed by caspase 8 activation (Fig. 2A), and SEK1 mediated the MEKK1 signaling
cascade to JNK during TRAIL treatment (Fig. 2B).
14-3-3 θ interacts with MEKK1, and its dissociation from MEKK1 by TRAIL treatment is
caspase 8-dependent
As mentioned by Widmann et al. (24), full-size MEKK1 activated JNK independent of its
truncated form (91 kDa) (Figs. 2A and 2B); 91 kDa of MEKK1 was only observed when
TRAIL was treated to cells that overexpressed MEKK1 (data not shown). These results do
not clearly elucidate the underlying mechanisms of MEKK1 activation. Widmann et al. (24)
suggested that 14-3-3 proteins, which are a family of serine/threonine binding proteins that
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are expressed ubiquitously (25), have anti-apoptotic functions exerted by directly
sequestering pro-apoptotic proteins, such as Bad (26,27). We examined the same possibility
of sequestration of MEKK1 activity by 14-3-3 and release of MEKK1 from 14-3-3. First, we
examined whether various 14-3-3 isotypes are cleaved by TRAIL treatment and found that
there was no cleavage of 14-3-3 (Fig. 3A). Then, we investigated the associations of
MEKK1 and various 14-3-3 isotypes. As shown in figure 3B, only 14-3-3 θ showed a
meaningful change with MEKK1 during TRAIL treatment. In DU-145 cells, the dissociation
of MEKK1 from 14-3-3 was inhibited by caspase 8 inhibitor (Fig. 3C), implying that
caspase 8 activity is necessary for 14-3-3 release and subsequent MEKK1 phosphorylation
and activation.
MEKK4 is responsible for p38 activation as well as JNK activation in TRAIL treatment
From the report indicating that MEKK4 can stimulate p38 as well as JNK activity (28),
MEKK4 involvement of p38 activation during TRAIL treatment was examined using siRNA
of MEKK4. As shown in figure 4A, p38 and JNK phosphorylation were repressed during
TRAIL treatment when MEKK4 expression was downregulated.. Additionally, MEKK4
catalytic activity was also affected by caspase 8 activation (Fig. 4B).
Discussion
In this study, we found that the MEKK family is responsible for JNK and p38
phosphorylations during TRAIL treatment. In our previous paper, we reported that UV-
induced JNK activation adopted EGFR-Grb2-MEKK1-SEK1-JNK (29); however, here, we
show that MEKK1/4-induced SEK1-JNK/p38 activation by TRAIL is caspase 8-dependent,
suggesting that Mst1 might also play a role as an upstream molecule of MEKK1 and
MEKK4 phosphorylations (12,30). As shown in many reports, MEKK1 itself can be
activated in various ways depending on the source of stimulation, e.g., UV light induces
MEKK1 activation through EGFR-Grb2, whereas TRAIL induces MEKK1 activation
through caspase 8-Mst1. In addition, MEKK1 can be also activated by the caspase 8-
independent GCK-MEKK1 signaling pathway mediated by TRAF2 (31). However, we do
not and cannot know exactly why there are multiple cellular processes that can lead to the
activation of MEKK1. It has been suggested that cells adopt specific signaling schemes to
appropriately accommodate the stimulations they experience. In the case of MAPKs
activation induced by TRAIL, Mst1 has been known to act as a putative MAPK kinase
kinase kinase (32), thus, functioning in a positive feedback pathway that amplifies the
apoptotic response through MAPK activation. However, the biological significance of
MAPK activation has only been emphasized in regard to its pro-apoptotic effects, despite
being known to have anti-apoptotic effects as well. Varfolomeev et al. (11) suggested that
kinase pathway activation by TRAIL was associated with increased production of the
chemokines IL-8 and MCP-1 and with enhanced macrophage migration for the promotion of
chemokine-supported phagocytosis of apoptotic cells. Interestingly, it has been reported that
MCP-1 also plays a role in prostate cancer invasion and metastasis (33,34), which suggests
that MAPK activation during TRAIL treatment may serve several functions in addition to its
role in apoptosis. We have already published the findings that cells from DU-145 developed
acquired resistance to TRAIL-induced apoptosis after TRAIL treatment and that pAkt and
Bcl-xL were involved in the process of acquired resistance (8). Also, several lines of
evidence show that the ability to resist apoptosis may enhance metastasis (35,36). Therefore,
in our next study, we will investigate whether and/or how much MAPKs activation induced
by TRAIL contributes to acquired TRAIL resistance, which allows for progression to
invasion or metastasis, by measuring MMP activity and MCP1 and IL-6 levels in vitro and/
or incidence and intensity of metastasis in vivo.
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Abbreviations used in this paper
TRAIL tumor necrosis factor-related apoptosis-inducing ligand
PAGE polyacrylamide gel electrophoresis
PARP poly(ADP-ribose) polymerase
MAPK mitogen-activated protein kinase
JNK c-Jun, NH2-terminal kinase
ERK extracellular signal-regulated kinase
MEK mitogen-activated protein kinase
MEKK1 MEK kinase 1
ASK1 apoptosis signal-regulating kinase 1
SEK1 stress-activated protein kinase/extracellular-signal regulated kinase
MLK mixed lineage kinase
TAK1 TGF-β activated-kinase
ROS reactive oxygen species
GCK germinal center kinase
TRAF2 TNF receptor-associated factor 2
Mst1 mammalian sterile 20-like kinase 1
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Figure 1.
Involvement of MEKK1 in MAPKs phosphorylation during TRAIL treatment. (A) Various
MAPKs phosphorylation induced by TRAIL treatment (200 ng/ml, 4 h) was examined after
transfection of control siRNA, ASK1 siRNA (left panel), or MEKK1 siRNA (right panel)
into DU-145 cells. (B) After TRAIL (200 ng/ml, 4 h) treatment of DU-145 cells that became
catalase-overexpressing via infection with an adenovirus expressing catalase (100 moi) or
DU-145 cells that became EGFP-overexpressing via infection with an adenovirus expressing
EGFP as a control (100 moi), phosphorylation of JNK was examined. C: control; T: TRAIL;
si-neg:si-negative
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Figure 2.
Caspase 8-dependent MEKK1 activation during TRAIL treatment. (A) DU-145 cells were
pretreated with caspase-8 inhibitor (Z-IETD-FMK 20 μM, 30 min), followed by TRAIL
treatment (200 ng/ml) for 2 or 4 h, and were lysed. Cell lysates were immunoprecipitated
with anti-MEKK1 antibody. MEKK1 catalytic activity in vitro was determined by
incubation with GST-SEK1 followed by GST-JNK1 as sequential substrates (upper panels).
Phosphorylated-JNK, JNK1, or MEKK1 were detected with anti-ACTIVE JNK, anti-JNK1,
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or anti-MEKK1 antibodies, respectively. Cell lysates (lower panel) were immunoblotted
with anti-PARP, anti-caspase-8, or anti-actin antibody, respectively. (B) Phosphorylated
JNK in control vector–transfected (si-neg) or pSilencersi SEK1 stably transfected (si-SEK1)
single cell clones was determined during TRAIL treatment from DU-145 cells. Lysates
containing equal amounts of protein (20 μg) were separated by SDS-PAGE and were
immunoblotted with anti-ACTIVE JNK, anti-JNK1, anti-SEK1 and anti-actin antibody,
respectively. C: control; T: TRAIL
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Figure 3.
14-3-3 isotypes and MEKK1 during TRAIL treatment. (A) Various 14-3-3 isotypes were
examined for cleavage by TRAIL (200 ng/ml) after various periods of time. (B) DU-145
cells were treated with TRAIL (200 ng/ml) for 2 h and lysed. Cell lysates were
immunoprecipitated with anti-14-3-3 θ (left panel) or 14-3-3 γ (right panel) and
immunoblotted with anti-14-3-3 θ/γ antibody or anti-MEKK1 antibody (upper panels). Cell
lysates (lower panel) were immunoblotted with MEKK1 antibody. (C) DU-145 cells were
pretreated with caspase-8 inhibitor (Z-IETD-FMK 20 μM, 30 min), followed by TRAIL
treatment (200 ng/ml) for 2 h, and were lysed. Cell lysates were immunoprecipitated with
anti-14-3-3 θ antibody and immunoblotted with anti-MEKK1 antibody (upper panels). Cell
lysates (lower panel) were immunoblotted with MEKK1 antibody, anti-PARP antibody,
caspase-8 antibody, or anti-actin antibody, respectively.
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Figure 4.
Involvement of MEKK4 in MAPKs phosphorylation during TRAIL treatment. (A) MAPKs
phosphorylation induced by TRAIL treatment (200 ng/ml, 4 h) was examined after
transfection of control siRNA or MEKK1 siRNA (left) or MEKK4 siRNA (right) into
DU-145 cells. (B) DU-145 cells were pretreated with caspase-8 inhibitor (Z-IETD-FMK 20
μM, 30 min), followed by TRAIL treatment (200 ng/ml) for 2 or 4 h, and were lysed. Cell
lysates were immunoprecipitated with anti-MEKK4 antibody. MEKK4 catalytic activity in
vitro was determined by incubation with GST-SEK1 followed by GST-JNK1 as sequential
substrates (upper panels). Phosphorylated-JNK1, JNK1, or MEKK4 were detected with anti-
ACTIVE JNK1, anti-JNK1, or anti-MEKK4 antibodies, respectively. Cell lysates (lower
panel) were immunoblotted with anti-PARP, anti-caspase-8, or anti-actin antibody,
respectively. C: control; T: TRAIL
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